首页>投融资
Kallyope
捐赠/众筹/授予
Kallyope Inc operates as a biotechnology company. The Company focuses on understanding gut-brain biology for transformational therapeutics to improve human health.In February 2022, Kallyope Inc closed a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group.In March 2020, the company announced $112 million series C financing.In December 2018, the company expanded about $21 million and bought the Series B round total to $87 million and raised $131 million in equity capital.In February 2018, the company raised US $66 million in a series B financing round.In December 2015, the company launched with a series A financing of US $44 million
基本信息
-
公司全称Kallyope Inc
-
类型肠脑轴机制新药开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15人以下
-
地址430 E 29th St NEW YORK NEW YORK 10016-8367; US; Telephone: +19083776454;
-
联系电话
-
邮箱info@kallyope.com
-
成立时间2015-01-01
投融资
-
2023-05-10捐赠/众筹/授予820万美元Bill and Melinda Gates Foundation
-
2022-02-15D轮2.36亿美元Alexandria Venture InvestmentsLux CapitalCasdin CapitalHartford HealthCare EndowmentMubadalaPolaris PartnersIllumina VenturesTao Capital PartnersThe Column GroupEuclidean CapitalDNS CapitalStepStone GroupParkwoodTwo Sigma Ventures
-
2020-03-25C轮1.12亿美元Lux CapitalCasdin CapitalPolaris PartnersThe Column GroupGreenspring AssociatesBill and Melinda Gates Foundation
-
2018-12-05B轮2100万美元Alexandria Venture InvestmentsLux CapitalPolaris PartnersIllumina VenturesTwo Sigma VenturesThe Column GroupEuclidean CapitalBill and Melinda Gates Foundation
-
2018-02-22B轮6600万美元Alexandria Venture InvestmentsLux CapitalPolaris PartnersIllumina VenturesThe Column GroupEuclidean CapitalTwo Sigma Ventures
-
2015-12-10A轮4400万美元IlluminaAlexandria Venture InvestmentsLux CapitalPolaris PartnersThe Column GroupTony Evnin
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息